IP Library › Granted Patent US 11,891,426
Granted Patent B2
US 11,891,426 · App. 16/954,002 · Granted Feb 6, 2024

CD19 variants

Inventors: Roy Lobb (Wellesley, MA); Paul Rennert (Holliston, MA); Benjamin Hackel (Edina, MN); Justin Klesmith (Roseville, MN)
Assignees: Aleta Biotherapeutics Inc.; Regents of The University of Minnesota
C07K14/70503A61K38/1774A61K39/39558A61K45/06C07K16/32A61K2039/505C07K2317/622C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,891,426
App. No.
16/954,002
Granted
Feb 6, 2024
Kind
B2
Abstract

CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.

Claims (14)

1. A CD19 variant having at least 99% sequence identity to SEQ ID NO:2 wherein,

the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2 selected from the following:

S/V/S; G/V/R; S/R/R; T/V/P; S/R/S; E/R/P; E/W/R; E/V/V; D/L/P; A/R/L; W/S/S; T/R/Q; R/V/R; E/E/V; Y/S/R; D/V/M; W/V/A; TN/F; R/A/F; E/C/S; E/R/R; D/V/R; S/V/A; T/A/S; H/F/R; T/V/R; T/M/S; S/V/R; H/V/S; S/F/N; N/L/P; D/V/S; W/T/A; D/A/S; G/V/K wherein the CD19 variant has improved binding to an anti-CD19 antibody relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2; or

the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2 selected from the following:

Y/S/T; V/G/D; A/Q/T; V/E/E; wherein the CD19 variant is more resistant to protease cleavage relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

2. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids S/V/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

3. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids S/V/S at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

4. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids G/V/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

5. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids S/R/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

6. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids S/R/S at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

7. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids W/S/S at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

8. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids Y/S/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

9. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids D/V/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

10. The CD19 variant of claim 1 , wherein the CD19 variant comprises amino acids T/V/R at positions 62/64/66 of the amino acid sequence of SEQ ID NO: 2.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 053867 FRAME: 0116. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 8, 2021
From: LOBB, ROY; RENNERT, PAUL
To: ALETA BIOTHERAPEUTICS INC.
Reel/Frame 054939/0313 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: KLESMITH, JUSTIN
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 053867/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: HACKEL, BENJAMIN
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 053867/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: LOBB, ROY; RENNERT, PAUL
To: ALETA BIOTHERAPEUTICS INC.
Reel/Frame 053867/0116 →
Continuity (2)
Provisional Application 62599211 · Dec 15, 2017
Related Publication 20210079060A1 · Mar 18, 2021